Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

88.46USD
20 Feb 2020
Change (% chg)

$-0.90 (-1.01%)
Prev Close
$89.36
Open
$89.00
Day's High
$89.56
Day's Low
$88.05
Volume
1,473,179
Avg. Vol
1,485,828
52-wk High
$92.40
52-wk Low
$72.36

Latest Key Developments (Source: Significant Developments)

FDA Says Abbott Vascular Recalls NC Trek RX And NC Traveler RX Coronary Dilatation Catheters Due To Failure Of Balloon To Deflate
Thursday, 20 Feb 2020 

Feb 19 (Reuters) - FDA: :FDA SAYS ABBOTT VASCULAR RECALLS NC TREK RX AND NC TRAVELER RX CORONARY DILATATION CATHETERS DUE TO FAILURE OF BALLOON TO DEFLATE .FDA SAYS HAS IDENTIFIED ABBOTT VASCULAR RECALL AS A CLASS I RECALL.FDA SAYS 13,891 NC TREK RX AND NC TRAVELER RX CORONARY DILATATION CATHETERS IN U.S. WERE RECALLED DUE TO FAILURE OF BALLOON TO DEFLATE.FDA SAYS ABBOT VASCULAR HAS RECEIVED 13 COMPLAINTS RELATED TO CORONARY DILATATION CATHETERS FAILURE, ONE DEATH HAS BEEN REPORTED.  Full Article

Abbott Laboratories Says It Expects Mid- To High Single-Digit Growth In Established Pharmaceuticals In Both Q1 And Full Year 2020- Conf. Call
Wednesday, 22 Jan 2020 

Jan 22 (Reuters) - Abbott Laboratories ::CEO SAYS CO IS WINNING NEW BUSINESS AT A HIGH RATE IN EUROPE FOR BLOOD AND PLASMA SCREENING SYSTEM ALINITY - CONF. CALL.SAYS IT EXPECTS FOREIGN EXCHANGE TO HAVE A NEGATIVE IMPACT OF AROUND 0.5% ON FULL YEAR REPORTED SALES- CONF. CALL.SAYS IT EXPECTS MID- TO HIGH SINGLE-DIGIT GROWTH IN ESTABLISHED PHARMACEUTICALS IN BOTH Q1 AND FULL YEAR 2020- CONF. CALL.SAYS IT EXPECTS NUTRITION UNIT TO GROW AROUND 4% FOR THE FULL YEAR- CONF. CALL.SAYS IT EXPECTS MID- TO HIGH SINGLE-DIGIT GROWTH OF DIAGNOSTICS UNIT FOR BOTH Q1 AND FULL YEAR- CONF. CALL.SAYS IT EXPECTS DOUBLE-DIGIT GROWTH OF MEDICAL DEVICES UNIT FOR BOTH Q1 AND FULL YEAR- CONF. CALL.SAYS PLANS TO ROLL LIBRE INTO NEW GEOGRAPHIES- CONF. CALL.SAYS THERE WILL BE MORE TV ADVERTISING, SALES FORCE EXPANSION AND MORE PARTNERSHIPS REGARDING LIBRE- CONF. CALL.SAYS PLANS TO ROLL OUT LIBRE 2.0 INTO SOME OF LIBRE 1 MARKETS- CONF. CALL.INCOMING CEO ROBERT FORD EXPECTS TO HAVE "SAME PHILOSOPHY" AS PREDECESSOR MILES WHITE- CONF. CALL.INCOMING CEO ROBERT FORD SAYS ABBOTT IS NOT LOOKING TO DO ANY DEALS RIGHT NOW- CONF. CALL.SAYS DIVIDEND RETURN TO SHAREHOLDERS REMAINS A PRIORITY- CONF. CALL.  Full Article

FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System With Up To Ten Year Battery Life For People Living With Chronic Pain
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - Abbott Laboratories ::FDA APPROVES ABBOTT'S "LOW DOSE," RECHARGE-FREE SPINAL CORD STIMULATION SYSTEM WITH UP TO TEN YEAR BATTERY LIFE* FOR PEOPLE LIVING WITH CHRONIC PAIN.ABBOTT LABORATORIES - PROCLAIM XR IS CURRENTLY UNDER REVIEW FOR CE MARK.  Full Article

Abbott And Sanofi Partner To Integrate Glucose Sensing And Insulin Delivery Technologies
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Abbott Laboratories ::ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED.ABBOTT LABORATORIES - ABBOTT AND SANOFI ARE PARTNERING TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32PER SHARE.  Full Article

Abbott Laboratories Reports Q2 Gaap Earnings Per Share $0.56 From Continuing Operations
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS SECOND-QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q2 GAAP EARNINGS PER SHARE $0.56 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.80 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.21 TO $3.27 FROM CONTINUING OPERATIONS.SEES Q3 ADJUSTED EARNINGS PER SHARE $0.83 TO $0.85 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q3 2019 GAAP EARNINGS PER SHARE $0.53 TO $0.55 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $2.06 TO $2.12 FROM CONTINUING OPERATIONS.RAISING FULL-YEAR GUIDANCE FOR ORGANIC SALES GROWTH TO 7 TO 8 PERCENT.FY2019 EARNINGS PER SHARE VIEW $3.22 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.85 -- REFINITIV IBES DATA.QTRLY SALES OF $ 7,979 MILLION VERSUS $ 7,767 MILLION REPORTED LAST YEAR.RAISING FULL-YEAR EPS FORECAST.FORECASTS SPECIFIED ITEMS FOR Q3 2019 OF $0.30 PER SHARE.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.15 PER SHARE..QTRLY PEDIATRIC SALES $1,051 MILLION, UP 0.1% ON A REPORTED BASIS.FY2019 REVENUE VIEW $31.99 BILLION -- REFINITIV IBES DATA.SAYS "OUR SALES GROWTH ACCELERATED AND IS SUSTAINABLE".QTRLY TOTAL NUTRITION SALES $1,875 MILLION, UP 0.9% ON REPORTED BASIS.QTRLY TOTAL DIAGNOSTICS SALES $1,905 MILLION, UP 1.7% ON REPORTED BASIS.Q2 REVENUE VIEW $8.00 BILLION -- REFINITIV IBES DATA.SECOND-QUARTER WORLDWIDE SALES INCREASED 7.5 PERCENT ON AN ORGANIC BASIS.  Full Article

Abbott Announces FDA Approval Of Alinity s System
Thursday, 11 Jul 2019 

July 11 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES FDA APPROVAL OF THE ALINITY™ S SYSTEM, THE LATEST TECHNOLOGY FOR SCREENING AND PROTECTING THE U.S. BLOOD AND PLASMA SUPPLY.ABBOTT LABORATORIES - ALINITY™ S SYSTEM WILL SCREEN U.S. BLOOD AND PLASMA SUPPLY FASTER AND MORE EFFICIENTLY WHILE MAINTAINING HIGHEST LEVELS OF ACCURACY.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 14 Jun 2019 

June 14 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott Reports First Quarter GAAP Earnings Per Share Of $0.38 From Continuing Operations
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS FIRST-QUARTER 2019 RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.63 FROM CONTINUING OPERATIONS.Q1 GAAP EARNINGS PER SHARE $0.38 FROM CONTINUING OPERATIONS.Q1 EARNINGS PER SHARE ESTIMATE $0.61 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q2 ADJUSTED EARNINGS PER SHARE $0.79 TO $0.81 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q2 2019 GAAP EARNINGS PER SHARE $0.47 TO $0.49 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.95 TO $2.05 FROM CONTINUING OPERATIONS.QTRLY TOTAL PEDIATRIC SALES $1,029 MILLION VERSUS $994 MILLION REPORTED LAST YEAR.FIRST-QUARTER WORLDWIDE SALES OF $7.5 BILLION INCREASED 2.0 PERCENT ON A REPORTED BASIS AND 7.1 PERCENT ON AN ORGANIC BASIS.PROJECTS STRONG FULL-YEAR OUTLOOK.QTRLY TOTAL NUTRITION SALES $1,792 MILLION VERSUS $1,756 MILLION REPORTED LAST YEAR.QTRLY TOTAL DIAGNOSTICS SALES $1,841 MILLION VERSUS $1,837 MILLION REPORTED LAST YEAR.ABBOTT FORECASTS SPECIFIED ITEMS FOR Q2 2019 OF $0.32 PER SHARE.SAYS "WE'RE RIGHT ON TRACK WITH OUR EXPECTATIONS TO START THE YEAR".ABBOTT FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.20 PER SHARE.BOARD OF DIRECTORS OF ABBOTT DECLARED COMPANY'S QUARTERLY DIVIDEND OF $0.32 PER SHARE.SAYS "WE'RE TARGETING ANOTHER YEAR OF STRONG SALES AND EARNINGS GROWTH".Q1 REVENUE VIEW $7.47 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.80 -- REFINITIV IBES DATA.  Full Article

Abbott Announces CE Mark For Alinity M Diagnostics System And Assays
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES CE MARK FOR ALINITY™ M DIAGNOSTICS SYSTEM AND ASSAYS, THE LATEST IN MOLECULAR TECHNOLOGY, TO HELP DELIVER CRITICAL TEST RESULTS AND BENEFITS TO PATIENTS.  Full Article

BRIEF-Abbott Laboratories Received CE Mark For New Gallant Implantable Cardioverter Defibrillator And Cardiac Resynchronization Therapy Defibrillator Devices

* ABBOTT LABORATORIES - RECEIVED CE MARK FOR NEW GALLANT IMPLANTABLE CARDIOVERTER DEFIBRILLATOR AND CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR DEVICES Source text for Eikon: Further company coverage: